{"entity":{"id":"nct00777153","kind":"trial","name":"Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","aka":[],"tldr":"A phase 3 trial of Cediranib in Glioma & glioblastoma, run by AstraZeneca, completed.","summary":"Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma is a phase 3 interventional study registered as NCT00777153 by AstraZeneca, with 423 participants recorded, started 2008-10 and reaching its primary completion in 2010-04. Interventions recorded: Cediranib, Cediranib, Lomustine Chemotherapy, Placebo Cediranib. Conditions recorded: Recurrent Glioblastoma.\n\nLinked to the drug Cediranib because the registry names it among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00777153","url":"https://clinicaltrials.gov/study/NCT00777153"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cediranib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00777153","phase":"3","setting":"A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone","sponsor":"AstraZeneca","enrolled":423,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00777153/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"cediranib","kind":"drug","name":"Cediranib","route":"/drugs/cediranib/"}]}}